Skip to main content
SpringerLink
Log in

La sclerosi multipla

  • Chapter
Costi sociali e aspetti farmacoeconomici

Part of the book series: Aspetti psico-sociali della sclerosi multipla ((APSSM,volume 4))

  • 231 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 19.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 24.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografia

  1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG (2000) Multiple sclerosis. N Engl J Med 343(13):939–952

    Article  Google Scholar 

  2. Pugliatti M, Sotgiu S, Rosati G (2002) The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104(3):182–191

    Article  PubMed  Google Scholar 

  3. Amato MP, Ponziani G (1999) Quantification of impairment in MS: discussion of the scales in use. Mult Scler 5(4):216–219

    Article  CAS  PubMed  Google Scholar 

  4. Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452

    CAS  PubMed  Google Scholar 

  5. Grimaud J, Auray JP, Collectif sep des villes et sep des champs (2004) Quality of life and economic cost of multiple sclerosis. Rev Neurol 160(1):23–34

    CAS  PubMed  Google Scholar 

  6. The IFNB multiple sclerosis study group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 43(4):655–661

    Google Scholar 

  7. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscolar interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol 39(3):285–294

    Article  CAS  PubMed  Google Scholar 

  8. PRISMS (prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) study group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352(9139):1498–1504

    Google Scholar 

  9. Johnson KP, Brooks BR, Cohen JA et al (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of the phase III multicenter, doubleblind, placebo-controlled trial. Neurology 45(7):1268–1276

    CAS  PubMed  Google Scholar 

  10. European study group on interferon beta-1b in secondary progressive MS (1998) Placebo-controlled multicentre randomized trial of interferon b-1b in treatment of secondary progressive multiple sclerosis. Lancet 352(9139):1491–1497

    Google Scholar 

  11. Hartung HP, Gonsette R, Konig N et al (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350):2018–2025

    Article  PubMed  Google Scholar 

  12. Goodin DS, Frohman EM, Garmany GP jr et al (2002) Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58(2):169–178

    CAS  PubMed  Google Scholar 

  13. Panitch H, Goodin DS, Francis G et al (2002) Evidence of Interferon Dose-response: Europian North American Compartative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 59(10):1496–1506

    CAS  PubMed  Google Scholar 

  14. Durelli L, Verdun E, Barbero P et al (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta 1-a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359(9316):1453–1460

    Article  CAS  PubMed  Google Scholar 

  15. Jacobs LD, Beck RW, Simon JH et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898–904

    Article  CAS  PubMed  Google Scholar 

  16. Comi G, Filippi M, Barkhof F et al (2001) Early treatment of Multiple Sclerosis Study Group. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576–1582

    Article  CAS  PubMed  Google Scholar 

  17. Filippini G, Munari L, Incorvaia B et al (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361(9357):545–552

    Article  CAS  PubMed  Google Scholar 

Download references

Authors
  1. M.P. Amato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Zipoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Italia

About this chapter

Cite this chapter

Amato, M., Zipoli, V. (2005). La sclerosi multipla. In: Costi sociali e aspetti farmacoeconomici. Aspetti psico-sociali della sclerosi multipla, vol 4. Springer, Milano. https://doi.org/10.1007/88-470-0401-2_1

Download citation

  • DOI: https://doi.org/10.1007/88-470-0401-2_1

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0327-9

  • Online ISBN: 978-88-470-0401-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation